Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efgartigimod - argenx

Drug Profile

Efgartigimod - argenx

Alternative Names: ARGX-113

Latest Information Update: 06 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Neonatal Fc receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myasthenia gravis
  • Phase II Idiopathic thrombocytopenic purpura; Pemphigus vulgaris

Most Recent Events

  • 07 Dec 2019 Pharmacokinetics data from a phase II trial in Idiopathic thrombocytopenic purpura presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-2019)
  • 24 Oct 2019 argenx plans the registrational phase III ADVANCE+ trial for Idiopathic thrombocytopenic purpura (IV) (NCT04225156)
  • 24 Oct 2019 argenx intends to launch efgartigimod for generalised Myasthenia gravis in 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top